Supriya Lifescience Ltd. News and Updates

Name: Latest research reports of Supriya Lifescience Ltd. authored by KRChoksey and published by - Trendlyne research reports.
Item: Supriya Lifescience Ltd.
Rating: 5
Author: KRChoksey

Keep track of all breaking news on Supriya Lifescience Ltd. from all sources in a single place.

Load latest

Supriya Lifescience Ltd.

14 Aug 2024

698.80

3.55%

Better product mix and geographical mix led to strong performance

Buy: Supriya Lifescience Ltd.

Target

KRChoksey

Supriya Lifescience’s revenue was in-line with our estimate. EBITDA beat our estimate due to lower-than-expected cost of goods sold and operating expenses.

Number of FII/FPI investors increased from 69 to 85 in Dec 2024 qtr.

Supriya Lifescience Ltd.

12 Aug 2024

698.80

3.55%

to see Rapid results content

Supriya Lifescience Ltd.

02 Aug 2024

698.80

3.55%

Supriya Lifescience promoter Wagh family's next-gen to helm company

Business Line

The management changes are effective immediately, from 1st August 2024

Supriya Lifescience Ltd. has gained 30.40% in the last 6 Months

Supriya Lifescience Ltd.

05 Jun 2024

698.80

3.55%

New product launches and new contracts to drive growth

Buy: Supriya Lifescience Ltd.

KRChoksey

Supriya Life science's revenue beat our estimate (+5.8%) due to growth in Vitamin and Anti-Histamine segment. The EBITDA beat our estimate (+22.4%) due to lower-than-expected employee expenses, and lower-than-expected other expenses.

Supriya Lifescience Ltd. has gained 30.40% in the last 6 Months

Supriya Lifescience Ltd.

29 May 2024

698.80

3.55%

Supriya Lifescience Results Earnings Call for Q4FY24

Conference Call with Supriya Lifescience Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.

audio

Supriya Lifescience Ltd.

26 Feb 2024

698.80

3.55%

Supriya Lifescience Aims To Double Revenue To Rs 1,000 Crore By FY27 Know Your Company

NDTV Profit

The manufacturer of active pharmaceutical ingredients is also planning a capex of Rs 100 crore in the next two-three years.

Supriya Lifescience Ltd. has gained 82.72% in the last 1 Year

Supriya Lifescience Ltd.

16 Feb 2024

698.80

3.55%

Supriya Lifescience Q3 Review - Strong Growth Across Board On Favorable Geographical, Product Mix: DRChoksey

NDTV Profit

Expansion into a more regulated market boosts the top-line

Number of FII/FPI investors increased from 69 to 85 in Dec 2024 qtr.

Supriya Lifescience Ltd.

14 Feb 2024

698.80

3.55%

Strong growth across the board on favorable geographical and product mix

Buy: Supriya Lifescience Ltd.

Recommendation Target

KRChoksey

For Q3FY24, SUPRIYA’s revenue grew by 33.2% YoY and stayed flat for QoQ at INR 1,401 Mn, while for 9MFY24, revenue grew by 29.3% YoY to INR 4,122 Mn. The Q3FY24 revenue growth was driven by analgesic/anti-pyretic/anaesthetic (49.0% of revenue in Q3FY24, +157.8% YoY), vitamin (14.0% of revenue, +14.0% YoY) and Anti-malarial (2.0% of revenue, +28.9% YoY), which was partially offset by anti-asthma (7.0% of revenue, -50.5% YoY), anti-Histamine (15.0% of revenue, -27.1% YoY) and anti-allergic (5.0% of revenue, -36.8% YoY). Geographically, Europe (42.0% contribution to Q3FY24 revenue vs 26.0% in Q3FY23) led the top-line momentum; Asia’s revenue contribution decreased to 42.0% from 50.0% in Q3FY23.

Supriya Lifescience .. has an average target of 740.00 from 1 broker.

Supriya Lifescience Ltd.

22 Dec 2023

698.80

3.55%

Pick of the Day (Short Term Delivery Call)

Accumulate: Supriya Lifescience Ltd.

SBI Securities

SLL has a niche product basket of 38 APIs with presence in therapeutic areas of Analgesics, Anti-histamine, vitamins, anti-asthmatics, anti-allergic and anti-malarial. The company has tied up with
Kalinga Institute of Technology for development of GelHeal and Quickblue Oral Kit.

Number of FII/FPI investors increased from 69 to 85 in Dec 2024 qtr.

Supriya Lifescience Ltd.

23 Nov 2023

698.80

3.55%

Solid revenue growth driven by volume increase

Accumulate: Supriya Lifescience Ltd.

Recommendation Target

KRChoksey

For Q2FY24, Supriya Lifescience's revenue grew 24.9% YoY and 6.1% QoQ to INR 1,401 Mn, while for H1FY24, revenue grew 27.4% YoY to 2,721 Mn. In terms of revenue break up, analgesic/anti-pyretic/anesthetic (56.0% share in Q2FY24) grew by 29.9% YoY, anti histamine (2.0% share in Q2FY24) grew by 21.8% YoY, vitamin (11.0% share in Q2FY24) grew by 26.3% YoY, anti-asthma (10.0% share in Q2FY24) grew by 26.2% YoY, anti-allergic (8.0% share in Q2FY24) grew by 31.9% YoY, anti-malarial (2.0% share in Q2FY24) grew by 3.8% YoY, and others (11.0% share in Q2FY24) grew by 3.4% YoY.